Cargando…

N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial

BACKGROUND: A subgroup of depressed patients with increased inflammatory activity was shown to be more susceptible to develop Treatment Resistant Depression (TRD). Earlier studies with anti-inflammatory drugs have shown benefits in the treatment of major depressive disorder (MDD), but the effects ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chenghao, Bosker, Fokko J., Li, Jie, Schoevers, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122706/ https://www.ncbi.nlm.nih.gov/pubmed/30176835 http://dx.doi.org/10.1186/s12888-018-1845-1

Ejemplares similares

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms
por: Rossell, Susan L., et al.
Publicado: (2016)

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)
por: Ellegaard, Pernille Kempel, et al.
Publicado: (2018)

The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case–control association study
por: Yang, Chenghao, et al.
Publicado: (2021)

Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study
por: Omranifard, Victoria, et al.
Publicado: (2014)

The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression: Protocol for a Phase 2, Double-Blind, Placebo-Controlled Study
por: Chinna Meyyappan, Arthi, et al.
Publicado: (2021)

N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial
por: Klauser, Paul, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder
por: Plank, Julia R., et al.
Publicado: (2022)

Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis
por: Jørgensen, Caroline Kamp, et al.
Publicado: (2021)

The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial
por: Liao, Yue, et al.
Publicado: (2022)

PM405. Sodium Benzoate Add-on Treatment for Refractory Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Lin, Chieh-Hsin, et al.
Publicado: (2016)

N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study
por: Mahakalkar, Sunil M., et al.
Publicado: (2017)

The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
por: Saya, Sibel, et al.
Publicado: (2023)

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial
por: Maraone, Annalisa, et al.
Publicado: (2023)

Prophylaxis of contrast-induced nephropathy in patients with impaired renal function: double-blind comparison of acetylcysteine, theophylline, acetylcysteine + theophylline and placebo
por: Huber, W, et al.
Publicado: (2005)

The therapeutic effect of N‐acetylcysteine as an add‐on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double‐blind, placebo‐controlled clinical trial
por: Padoei, Fateme, et al.
Publicado: (2022)

Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder
por: Abdallah, Mahmoud S., et al.
Publicado: (2021)

Can loss of agency and oppositional perturbation associated with antidepressant monotherapy and low-fidelity psychological treatment dilute the benefits of guideline-consistent depression treatment at the population level?
por: Ormel, Johan, et al.
Publicado: (2020)

Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial
por: Otte, Christian, et al.
Publicado: (2020)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder
por: Honeycutt, Duncan C., et al.
Publicado: (2022)

A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol
por: Maier, Alice, et al.
Publicado: (2020)

Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study
por: Chen, Yiyi, et al.
Publicado: (2019)

Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
por: Huang, Yuxin, et al.
Publicado: (2021)

Lack of association of FKBP5 SNPs and haplotypes with susceptibility and treatment response phenotypes in Han Chinese with major depressive disorder: A pilot case–control study (STROBE)
por: Yang, Chenghao, et al.
Publicado: (2021)

Beneficial and harmful effects of antidepressants versus placebo, ‘active placebo’, or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses
por: Juul, Sophie, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial
por: Shimizu, Shinobu, et al.
Publicado: (2020)

A randomized, double-blinded, placebo-controlled clinical trial of duloxetine hydrochloride enteric-coated tablets in the treatment of refractory chronic cough
por: Wang, Shengyuan, et al.
Publicado: (2023)

Efficacy of celecoxib add-on treatment for immuno-metabolic depression: Protocol of the INFLAMED double-blind placebo-controlled randomized controlled trial
por: Zwiep, J.C., et al.
Publicado: (2022)

Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression
por: Blampied, Meredith, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy
por: Richards, Cynthia, et al.
Publicado: (2017)

Protocol for a pilot randomised, double-blind, placebo-controlled trial for assessing the feasibility and efficacy of faecal microbiota transplantation in adolescents with refractory irritable bowel syndrome: FAIS Trial
por: Zeevenhooven, Judith, et al.
Publicado: (2020)

Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial
por: Palmer, Edward R., et al.
Publicado: (2023)

Prospective, randomized, double-blind, placebo-controlled phase IIa clinical trial on the effects of an estrogen-progestin combination as add-on to inpatient psychotherapy in adult female patients suffering from anorexia nervosa
por: Paslakis, Georgios, et al.
Publicado: (2018)

PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
por: Au-Yeung, Sheena Kristine, et al.
Publicado: (2022)

A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder
por: Chen, Joseph C. C., et al.
Publicado: (2020)

The efficacy of gabapentin for the treatment of refractory cough associated with interstitial lung disease: study protocol for a randomized, double-blind and placebo-controlled clinical trial
por: Gao, Ronglin, et al.
Publicado: (2022)

Homeopathy for Depression - DEP-HOM: study protocol for a randomized, partially double-blind, placebo controlled, four armed study
por: Adler, Ubiratan C, et al.
Publicado: (2011)

A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders
por: Ghanizadeh, Ahmad, et al.
Publicado: (2013)

N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis
por: Conus, Philippe, et al.
Publicado: (2018)

Efficacy of approach bias modification as an add-on to smoking cessation treatment: study protocol for a randomized-controlled double-blind trial
por: Wittekind, Charlotte E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_am17poij2kup23dqj3hu0j1sgg